Get the Stockscreener App
0.4362
1.20%
-0.0053
After Hours:
.45
0.0138
+3.16%
Nexalin Technology Inc stock is traded at $0.4362, with a volume of 66,605.
It is down -1.20% in the last 24 hours and down -29.65% over the past month.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
See More
Previous Close:
$0.4415
Open:
$0.453
24h Volume:
66,605
Relative Volume:
0.21
Market Cap:
$8.14M
Revenue:
$174.80K
Net Income/Loss:
$-8.85M
P/E Ratio:
-0.6334
EPS:
-0.6887
Net Cash Flow:
$-4.37M
1W Performance:
-16.44%
1M Performance:
-29.65%
6M Performance:
-47.83%
1Y Performance:
-82.05%
1-Day Range:
$0.4302
$0.4552
1-Week Range:
$0.4175
$0.54
52-Week Range:
$0.3679
$2.57
Nexalin Technology Inc Stock (NXL) Company Profile
Name
Nexalin Technology Inc
Sector
Industry
Phone
(832) 260-0222
Address
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.4362 | 8.23M | 174.80K | -8.85M | -4.37M | -0.6887 |
|
ABT
Abbott Laboratories
|
111.04 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
370.50 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
93.01 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.99 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
83.89 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Nexalin Technology Inc Stock (NXL) Latest News
NXL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Hedge Fund Bets: What are analysts price targets for Nexalin Technology Inc Equity Warrant2025 Market WrapUp & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Nexalin Advances Pivotal HALO Clarity Trial for Insomnia - TipRanks
Nexalin Announces 150-Patient Pivotal HALO Clarity Trial to Support Planned De Novo FDA Submission - TradingView
Nexalin (Nasdaq: NXL) advances pivotal HALO Clarity insomnia trial toward FDA de novo bid - Stock Titan
Nasdaq Moves: Can Nexalin Technology Inc Equity Warrant continue delivering strong returns2025 Growth vs Value & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Nexalin Launches Pivotal HALO Clarity Trial To Support Planned FDA Submission For Insomnia - Nasdaq
Nexalin announces pivotal Halo(TM) Clarity trial - marketscreener.com
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market - The Manila Times
Drug-free insomnia device trial targets 30 million adults - Stock Titan
EXCLUSIVE: Penny Stock Nexalin Advances Pivotal Trial Aiming To Tackle Severe Insomnia - Bitget
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders - Bitget
Nexalin Technology, Inc. Applauds Bipartisan Congressional Support for Deep Brain Neurostimulation Research and Expanding Access for Veterans - Quiver Quantitative
Congress boosts brain stimulation research for veterans, with Nexalin involved - Stock Titan
Can Nexalin Technology Inc. Equity Warrant be recession proofMarket Sentiment Summary & Reliable Momentum Entry Alerts - mfd.ru
Will Nexalin Technology Inc. Equity Warrant outperform during market ralliesPortfolio Value Summary & Weekly High Conviction Ideas - mfd.ru
Is Nexalin Technology Inc. stock forming a cup and handleShort Setup & Free Weekly Chart Analysis and Trade Guides - mfd.ru
Aug Intraday: Will Nexalin Technology Inc Equity Warrant outperform during market rallies2025 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
Breakout Move: What are CCTGs earnings expectations2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
NXL Should I Buy - Intellectia AI
A | Can ONFO stock beat analyst upgradesJuly 2025 Highlights & Target Return Focused Picks - mfd.ru
What’s Nexalin Technology Inc. Equity Warrant’s historical returnEarnings Recap Report & Weekly High Potential Alerts - mfd.ru
Will Nexalin Technology Inc. Equity Warrant stock benefit from sector rotation2025 AllTime Highs & Verified Stock Trade Ideas - mfd.ru
Market Leaders: Will Nexalin Technology Inc benefit from geopolitical trendsInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
NXL Technical Analysis & Stock Price Forecast - Intellectia AI
Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Aug Gainers: Is RSVR a turnaround storyJuly 2025 Macro Moves & Safe Capital Growth Plans - baoquankhu1.vn
Nexalin Technology receives Nasdaq bid price deficiency notice - MSN
Risk Hedge: Can Nexalin Technology Inc. Equity Warrant outperform in the next rallyJuly 2025 Reactions & Community Consensus Trade Signals - mfd.ru
SEC Filings | Track, Search, and Analyze Public Company Disclosures - SECFilings.com
Decliners Report: Can Nexalin Technology Inc deliver consistent dividendsWeekly Trend Recap & Daily Volume Surge Signals - baoquankhu1.vn
Market Pulse: Will Nexalin Technology Inc benefit from geopolitical trendsQuarterly Growth Report & Technical Pattern Alert System - baoquankhu1.vn
Nexalin Launches NeuroCare, An AI Virtual Clinic for Brain Health Disorders - AIM Media House
Aug Drivers: Does Nexalin Technology Inc Equity Warrant have strong fundamentalsStop Loss & Verified High Yield Trade Plans - baoquankhu1.vn
Nexalin Technology stock rises after launching AI-powered virtual clinic By Investing.com - Investing.com Australia
Nexalin Technology stock rises after launching AI-powered virtual clinic - Investing.com
Nexalin Technology, Inc. Launches NeuroCare® Virtual Clinic Platform in Collaboration with UC San Diego to Enhance Brain Health Treatment Access and Monitoring - Quiver Quantitative
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care - ChartMill
EXCLUSIVE: Nexalin Launches AI-Powered Virtual Clinic For Brain Health For Home Settings - Benzinga
Nexalin Expands Peer-Reviewed Evidence For DIFS Non-Invasive Brain Stimulation - Nasdaq
Nexalin reports brain imaging studies validate its neurostimulation tech By Investing.com - Investing.com Nigeria
Nexalin reports brain imaging studies validate its neurostimulation tech - Investing.com
Nexalin Technology, Inc. Showcases Validation of DIFS™ Neurostimulation Technology Through Extensive Clinical Research - Quiver Quantitative
Nexalin Highlights its Expanding Body of Peer-Reviewed - GlobeNewswire
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation - Yahoo Finance
Rate Hike: Should I invest in Nexalin Technology Inc Equity Warrant before earningsJuly 2025 Catalysts & Low Drawdown Momentum Ideas - baoquankhu1.vn
CEO Moves: How is CRDA managing supply chain issuesWeekly Investment Report & AI Enhanced Trading Signals - baoquankhu1.vn
Is Nexalin Technology Inc. likely to announce a buyback2025 Price Targets & Scalable Portfolio Growth Methods - mfd.ru
Does Nexalin Technology Inc. Equity Warrant have strong fundamentalsAnalyst Downgrade & Verified Entry Point Signals - mfd.ru
What is Nexalin Technology Inc.’s book value per shareWeekly Stock Summary & Reliable Breakout Stock Forecasts - mfd.ru
Nexalin Technology receives Nasdaq listing status notification - Medical Buyer
Nexalin Technology Inc Stock (NXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nexalin Technology Inc Stock (NXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shelton Carolyn Hamby | Sr. VP - Quality, Regulatory |
Mar 12 '25 |
Buy |
2.20 |
6,000 |
13,200 |
30,000 |
2.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):